Johnson & Johnson And Tianjin Cancer Hospital To Conduct Joint Drug Research
This article was originally published in PharmAsia News
Johnson & Johnson and Cancer Hospital of Tianjin Medical University have signed an MOU to jointly develop oncology drugs. Both parties are also discussing the possibility of setting up an oncology R&D collaboration center in Tianjin's Binhai Hi-tech Industrial Park. Cancer Hospital is one of China's largest tumor prevention and treatment bases, housing an advanced tissue bank for tumor specimens. With its strong clinical techniques and resources, the hospital will make an ideal partner for Johnson & Johnson, which seeks to build up a cancer drug R&D base in Asia Pacific. Areas of cooperation will cover animal model studies, local and global clinical trials, technology and knowledge transfer, as well as training for clinicians and researchers. (Click here for more - Chinese language)
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.